Search Results

Vaccine biotech Gritstone bio is filing for bankruptcy while securing a stalking horse bid from an unnamed party, which the company hopes will save its clinical research in cancer and infectious disease.

Primarily known as an immunology and neuroscience company, AbbVie wanted to put the biopharma world on notice during its J.P. Morgan presentation: its oncology portfolio is underappreciated. This week, the Illinois-based company dove into the sizzling PD-1/VEGF space with a licensing deal with China-based RemeGen.

Gritstone bio, Inc. today announced the appointment of Stephen Webster to its Board of Directors.

Looking for a job in oncology? Check out the BioSpace list of nine companies hiring life sciences professionals like you.

As clinical research evolves, disruptive trial designs are reshaping how oncology advances. By integrating novel methodologies, strategic innovation, and patient-centered approaches, MEDSIR is driving a new era in cancer research, one that accelerates development, enhances efficiency, and delivers more meaningful therapeutic progress for patients worldwide.

Gritstone bio, Inc. today announced that management will be participating in the following investor and scientific conferences.

Gritstone bio, Inc. today announced that management will be participating in the following investor conference.

Gritstone bio, Inc. announced that the Compensation Committee of the company’s Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 6,850 shares of its common stock with an exercise price of $0.75, which is equal to the closing price of Gritstone’s common stock on June 7, 2024, the date of the grant.

Gritstone bio, Inc., a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced an approximately 40% reduction of its workforce.